Investors
Zelira Half Yearly Report FY22/23
March 1, 2023
https://www.youtube.com/watch?v=e70YU5MorQw
Investor Webinar: HOPE® 1 SPV created to fund Ph.2 and Ph.3 US FDA trials
Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.
February 22, 2023